RESEARCH TRIANGLE PARK, N.C. — October 3, 2025 — Leads & Copy — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that its board’s compensation committee has granted newly-hired employees stock options for 115,000 shares and restricted stock units (RSUs) covering 91,450 shares of BioCryst common stock. These options and RSUs, granted on October 1, 2025, serve as inducements for the employees joining BioCryst and align with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $7.37 per share, equivalent to BioCryst’s common stock closing price on the grant date. They vest in four equal annual installments from the grant date anniversary, contingent on continued service. Each option has a 10-year term and is subject to BioCryst’s Inducement Equity Incentive Plan and relevant agreements.
BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The company develops oral small-molecule and protein therapeutics, including ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor. BioCryst is advancing a pipeline of small-molecule and protein therapies.
Contact:
Investors: investorrelations@biocryst.com
Media: media@biocryst.com
Source: BioCryst Pharmaceuticals
